Traders should monitor initiation of the DUBLIN-4 trial and further clinical data from plinabulin combination studies, particularly in immunotherapy-resistant NSCLC. The progress at SEED Therapeutics, backed by Eli Lilly and Eisai, adds optionality. Despite a small shareholder base, the survival data and confirmatory trial plan could attract biotech investors focused on late-stage oncology catalysts.
Price Chart
Executive Summary
BeyondSpring reported its 2025 financial results and highlighted significant clinical progress for its lead asset, Plinabulin, including a statistically significant overall survival benefit in a Phase 3 NSCLC trial (DUBLIN-3) and plans to initiate a confirmatory Phase 3 trial (DUBLIN-4). The company also announced early data suggesting Plinabulin may overcome resistance to PD-1/PD-L1 therapies, while SEED Therapeutics, its equity investee, dosed the first patient in a Phase 1a trial for ST-01156. Financially, the company reduced its net loss from continuing operations and strengthened its balance sheet with $12.6M in cash and a $30M financing at SEED.
Key Financial Metrics
Key Facts
- Plinabulin + docetaxel showed statistically significant OS benefit in EGFR wild-type NSCLC (HR=0.72, p=0.0078) in DUBLIN-3 Phase 3 trial
- DUBLIN-4, a global confirmatory Phase 3 trial, is planned in biomarker-selected NSCLC patients post-immunotherapy
- Early data show plinabulin may restore sensitivity to PD-1 inhibitors, with 7.0-month PFS and 66% 24-month OS in PD-1-resistant NSCLC
- SEED Therapeutics dosed first patient in Phase 1a for ST-01156, an oral RBM39 degrader, after IND clearance in U.S. and China
- SEED completed $30M Series A-3 financing and appointed new CFO/CBO
- Net loss from continuing operations decreased to $8.7M in 2025 from $8.9M in 2024
- Cash, cash equivalents, and short-term investments totaled $12.6M as of December 31, 2025
Financial Impact
Reduced operating loss in continuing operations by $235K YoY; $35.4M in gross proceeds from partial sale of SEED shares; $30M additional financing at SEED level
Risk Factors
- DUBLIN-4 trial may not replicate DUBLIN-3 results
- Plinabulin remains unapproved; regulatory approval not guaranteed
- BYSI's market cap is small ($65M), making it highly volatile and sensitive to funding risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262191 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $0.6450 $0.5870 | ▼ −8.99% | ▼ −8.01% | $0.4900 (−24.03%) |
Oct 2, 2026 24d ago | 8-K | $0.7860 $0.6155 | ▲ +21.69% | ▲ +22.11% | $0.4900 (+37.66%) |
Sep 29, 2026 28d ago | 8-K | $0.7733 $0.6923 | ▼ −10.47% | ▼ −12.42% | $0.4900 (−36.64%) |
Sep 29, 2026 28d ago | 424B5 | $0.7733 $0.6923 | ▲ +10.47% | ▲ +12.42% | $0.4900 (+36.64%) |
Sep 18, 2026 5w ago | 8-K | $0.7400 $1.12 | ▼ −51.35% | ▼ −52.37% | $0.4900 (+33.78%) |
Sep 3, 2026 7w ago | DEFA14A | $0.6181 $0.7600 | ▲ +22.96% | ▲ +24.17% | $0.4900 (−20.72%) |
Aug 14, 2026 10w ago | 8-K | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4900 (−31.13%) |
Aug 14, 2026 10w ago | Press Release | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4900 (−31.13%) |
Jun 4, 2026 20w ago | 8-K | $1.71 $1.65 | ▼ −3.51% | ▼ −0.96% | $0.4900 (−71.35%) |
Jun 2, 2026 21w ago | Press Release | $1.70 $1.72 | ▲ +1.18% | ▲ +4.14% | $0.4900 (−71.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers